Cambridge, United States
Satellite Bio, founded in 2019, is revolutionizing regenerative medicine by developing Tissue Therapeutics, targeting humankind's most challenging diseases. Through their innovative SAT (Satellite Adaptive Tissues) platform, this U.S.-based company creates bioengineered tissues, termed Satellites, designed to restore and enhance organ function.
The company’s groundbreaking approach involves transforming various cell types into tissues capable of responding robustly to complex, multifactorial diseases. This strategic capability positions Satellite Bio at the forefront of a novel category in medicine, promising impactful therapeutic solutions.
Significant investor backing, like the recent $110.00M Series A funding from Polaris Partners, aMoon, Catalio Capital Management, Section 32, Waterman Ventures, and Lightspeed, underscores confidence in their potential. As they push forward, Satellite Bio is committed to delivering transformative healthcare advancements and setting new standards in regenerative medicine.
